NAPLEX Quiz: Drug Recalls And Shortages

What this quiz covers

This quiz focuses on Drug Recalls And Shortages, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Serum potassium and serum creatinine within 1–2 weeks after the ACE inhibitor switch (correct answer)
2. Thyroid-stimulating hormone in 6 weeks
3. Absolute neutrophil count weekly for 1 month
4. Serum magnesium 24 hours after the first dose

Explanation: This question tests monitoring requirements when switching between ACE inhibitors. The key patient-specific factor is that both medications are ACE inhibitors with similar effects on potassium and renal function, though the patient is switching to a different agent. Option A is correct because ACE inhibitors can cause hyperkalemia and affect renal function, and these parameters should be rechecked 1-2 weeks after any ACE inhibitor initiation or change, even when switching within the class. Option B (TSH) is unrelated to ACE inhibitor therapy. Option C (neutrophil count) is not routinely monitored for ACE inhibitors. Option D (magnesium) is not specifically affected by ACE inhibitors. The clinical pearl is that even when switching between agents in the same class, key safety parameters (potassium and renal function for ACE inhibitors) should be monitored to ensure the new agent is tolerated similarly to the previous one.

Question 2

1. Advise the patient to continue warfarin until the next scheduled INR check because his last INR was therapeutic
2. Instruct the patient to stop using the recalled lot immediately, dispense warfarin 5 mg tablets from an unaffected lot, and arrange an expedited INR check with prescriber notification (correct answer)
3. Switch the patient to rivaroxaban 20 mg by mouth once daily today without prescriber involvement to avoid any INR fluctuations
4. Dispense warfarin 4 mg tablets from an unaffected lot and instruct the patient to take one tablet daily to reduce bleeding risk from the recall

Explanation: This question tests the pharmacist's response to a drug recall involving a high-risk medication with potential superpotency. The key patient-specific factor is that the patient has already taken today's dose from the recalled lot and warfarin has a narrow therapeutic index where superpotency could cause dangerous bleeding. Option B is correct because it addresses immediate patient safety by stopping the recalled product, ensures continuity of anticoagulation therapy with an unaffected lot at the same dose, and includes critical monitoring with an expedited INR check and prescriber notification. Option A is incorrect and dangerous because continuing a potentially superpotent warfarin could lead to supratherapeutic INR and bleeding. Option C is inappropriate because switching anticoagulants requires prescriber involvement and careful transition planning. Option D is incorrect because arbitrarily reducing the dose without knowing the actual potency could lead to subtherapeutic anticoagulation. The clinical pearl is that drug recalls involving narrow therapeutic index medications require immediate action, continued therapy with safe product, enhanced monitoring, and prescriber communication.

Question 3

1. Dispense the recalled ciprofloxacin because the contamination risk is low and treatment should not be delayed
2. Contact the prescriber to change therapy to trimethoprim-sulfamethoxazole double strength (160/800 mg) by mouth twice daily for 14 days if local susceptibility supports use (correct answer)
3. Switch to azithromycin 500 mg by mouth once daily for 3 days without prescriber consultation
4. Change to nitrofurantoin 100 mg by mouth twice daily for 5 days because it is effective for all urinary tract infections

Explanation: This question tests appropriate antibiotic substitution during a drug recall for pyelonephritis treatment. The key patient-specific factor is uncomplicated pyelonephritis requiring effective oral therapy, with the prescribed fluoroquinolone unavailable due to contamination risk. Option B is correct because trimethoprim-sulfamethoxazole is an appropriate alternative for pyelonephritis when local susceptibility supports its use, the duration (14 days) is appropriate for this indication, and it involves prescriber communication for the therapeutic change. Option A is dangerous because dispensing contaminated medication violates patient safety. Option C is incorrect because azithromycin is not recommended for pyelonephritis and the duration is too short. Option D is inappropriate because nitrofurantoin doesn't achieve adequate tissue levels for pyelonephritis treatment despite being effective for cystitis. The clinical pearl is that pyelonephritis requires antibiotics with good tissue penetration and appropriate duration; during shortages, alternatives must be selected based on local resistance patterns with prescriber involvement.

Question 4

1. Switch to enalapril 10 mg by mouth twice daily (correct answer)
2. Switch to losartan 25 mg by mouth once daily
3. Switch to captopril 12.5 mg by mouth once daily
4. Discontinue lisinopril and continue amlodipine alone without additional therapy until lisinopril is available

Explanation: This question tests therapeutic interchange during a drug shortage for an ACE inhibitor in a patient with diabetes. The key patient-specific factor is that the patient has diabetes, making ACE inhibitors or ARBs preferred for renal protection, and she is currently well-controlled on combination therapy. Option A is correct because enalapril 10 mg twice daily provides an equivalent ACE inhibitor dose to lisinopril 20 mg daily, maintaining the same drug class benefits including renal protection in diabetes. Option B (losartan 25 mg) is suboptimal because it's a low starting dose of an ARB that may not maintain blood pressure control. Option C (captopril 12.5 mg once daily) is incorrect due to inadequate dosing - captopril requires multiple daily doses and this is below the typical starting dose. Option D is inappropriate because discontinuing antihypertensive therapy for 6 weeks could lead to uncontrolled hypertension and loss of renal protection. The clinical pearl is that during ACE inhibitor shortages, switching to another ACE inhibitor at equivalent doses maintains therapeutic benefits, while ARBs are reasonable alternatives if ACE inhibitors are unavailable.

Question 5

1. Convert to amoxicillin chewable tablets 875 mg by mouth twice daily for 10 days
2. Convert to amoxicillin chewable tablets 250 mg: 3.5 tablets by mouth twice daily for 10 days (correct answer)
3. Convert to amoxicillin chewable tablets 500 mg: 1.75 tablets by mouth twice daily for 10 days
4. Convert to amoxicillin chewable tablets 250 mg: 4 tablets by mouth twice daily for 10 days

Explanation: This question tests dosage form conversion calculations during a drug shortage. The patient needs amoxicillin 880 mg (11 mL × 80 mg/mL) twice daily, requiring conversion to chewable tablets. To achieve 880 mg per dose using 250 mg tablets: 880 mg ÷ 250 mg/tablet = 3.52 tablets, which rounds to 3.5 tablets. Option B is correct with 3.5 tablets of the 250 mg strength twice daily providing the closest dose to the prescribed 880 mg. Option A (875 mg tablets) would provide a similar total dose but doesn't match the calculation. Option C (1.75 tablets of 500 mg) would give 875 mg, which is acceptable but the question asks for 250 mg tablet conversion. Option D (4 tablets of 250 mg) would provide 1000 mg, representing a significant overdose. The clinical pearl is that when converting between dosage forms during shortages, maintain the prescribed dose as closely as possible using available strengths, and consider the practicality of tablet splitting for pediatric patients.

Question 6

1. Daily fasting and pre-meal self-monitored blood glucose with close follow-up for hypoglycemia/hyperglycemia during the switch (correct answer)
2. International normalized ratio (INR) within 72 hours of the switch
3. Serum digoxin concentration 5–7 days after the switch
4. Peak expiratory flow rate twice daily for 2 weeks after the switch

Explanation: This question tests monitoring requirements when switching between insulin products due to a recall. The key patient-specific factor is that the patient uses basal-bolus insulin therapy and is switching from a recalled insulin glargine with potential underdosing to a biosimilar product. Option A is correct because blood glucose monitoring is essential when switching insulin products, especially when the recalled product may have been underdosing (leading to potential hyperglycemia) and the new product may provide full dosing (risk of hypoglycemia if the patient adapted to underdosing). Option B (INR) is irrelevant as the patient is not on anticoagulation. Option C (digoxin level) is inappropriate as the patient is not taking digoxin. Option D (peak flow) is unnecessary as this change doesn't affect respiratory function. The clinical pearl is that insulin product switches, particularly involving recalls for dosing issues, require intensive glucose monitoring to detect and prevent hypoglycemia or hyperglycemia during the transition period.

Question 7

1. Document the drug shortage details (product, duration, attempts to obtain), prescriber communication, therapy change with dose, patient counseling, and follow-up/monitoring plan in the patient profile (correct answer)
2. Document only that the patient was unhappy about the shortage to justify the medication change
3. Document the new medication and dose only; omit shortage details to avoid liability
4. Document that the patient was instructed to use leftover metformin from prior fills until new stock arrives, regardless of expiration date

Explanation: This question tests proper documentation requirements for drug shortage interventions. The key factor is ensuring complete documentation for continuity of care, liability protection, and quality assurance. Option A is correct because comprehensive documentation should include the shortage details, communication with prescriber, specific therapy changes, patient counseling provided, and monitoring plans - all essential for patient safety and professional practice standards. Option B is inadequate because it only documents patient satisfaction without clinical details. Option C is insufficient and potentially dangerous because omitting shortage information could lead to confusion about therapy changes. Option D is inappropriate and unsafe because it documents advice to use expired medications. The clinical pearl is that drug shortage interventions require the same thorough documentation as any clinical intervention, including the reason for change, prescriber collaboration, patient education, and follow-up plans to ensure safe transitions in therapy.

Question 8

1. Switch to metformin extended-release 1000 mg by mouth twice daily
2. Switch to metformin extended-release 2000 mg by mouth once daily with the evening meal (correct answer)
3. Discontinue metformin and increase empagliflozin to 25 mg by mouth once daily without prescriber input
4. Switch to metformin extended-release 500 mg by mouth once daily

Explanation: This question tests therapeutic alternatives for metformin during a shortage, focusing on formulation switches and dose equivalence in type 2 diabetes management. The key patient-specific factors are the patient's current 1000 mg twice daily immediate-release dose, hemoglobin A1c of 7.4%, and normal renal function. Switching to metformin extended-release 2000 mg once daily with the evening meal is the best choice as it maintains total daily dose and glycemic control with a convenient once-daily regimen. Twice-daily extended-release lacks the evening dosing benefit for tolerability, increasing empagliflozin without prescriber input is inappropriate, and 500 mg once daily is subtherapeutic. A transferable clinical pearl is that metformin IR to ER conversions typically match total daily dose, with ER taken with meals to minimize GI effects. Pharmacists should apply a framework evaluating renal function, A1c control, and patient adherence when selecting alternatives.

Question 9

1. Enalapril 10 mg by mouth once daily
2. Enalapril 20 mg by mouth once daily (correct answer)
3. Enalapril 40 mg by mouth once daily
4. Enalapril 2.5 mg by mouth once daily

Explanation: This question tests therapeutic alternatives for lisinopril during shortage, focusing on equipotent ACE inhibitor conversion. The key patient-specific factor is the stable 20 mg lisinopril dose for hypertension. Enalapril 20 mg once daily is the best choice as it provides direct dose equivalence. 10 mg or 2.5 mg are subtherapeutic, 40 mg exceeds equivalence risking hypotension. A transferable clinical pearl is that lisinopril and enalapril share 1:1 dose conversion for most patients. Pharmacists should employ a framework using conversion charts and monitoring blood pressure post-switch.

Question 10

1. Metformin immediate-release 2000 mg by mouth once daily with the evening meal
2. Metformin immediate-release 1000 mg by mouth twice daily with meals (correct answer)
3. Metformin immediate-release 500 mg by mouth once daily
4. Stop metformin and continue semaglutide only until supply returns

Explanation: This question tests therapeutic alternatives for metformin extended-release during shortage, emphasizing formulation switches and dose equivalence. The key patient-specific factors are the 2000 mg once-daily extended-release dose and availability of immediate-release 1000 mg tablets. Metformin immediate-release 1000 mg twice daily with meals is the best choice as it maintains total daily dose and minimizes GI upset. Once-daily 2000 mg immediate-release risks tolerability issues, 500 mg is subtherapeutic, stopping metformin disrupts control. A transferable clinical pearl is that ER to IR switches often divide doses with meals for better absorption and tolerance. Pharmacists should use a framework calculating total dose and assessing patient factors like meals.

Question 11

1. Nitrofurantoin monohydrate/macrocrystals 100 mg by mouth twice daily for 5 days (correct answer)
2. Cephalexin 250 mg by mouth once daily for 3 days
3. Ciprofloxacin 250 mg by mouth once daily for 1 day
4. Dispense the recalled trimethoprim-sulfamethoxazole lot and advise the patient to split tablets if needed

Explanation: This question tests therapeutic alternatives during a trimethoprim-sulfamethoxazole recall for uncomplicated cystitis, focusing on guideline-based options. The key patient-specific factors include the uncomplicated infection, normal renal function, and no allergies or pregnancy. Nitrofurantoin 100 mg twice daily for 5 days is the best choice as it is a first-line alternative with appropriate duration and spectrum for cystitis. Cephalexin dosing is incorrect (should be higher frequency), ciprofloxacin dosing is inadequate, dispensing recalled product risks error. A transferable clinical pearl is that UTI treatments should follow IDSA guidelines, prioritizing short courses for uncomplicated cases. Pharmacists should use a decision framework evaluating allergy, renal function, and local resistance for antibiotic substitutions.

Question 12

1. Oseltamivir 30 mg capsule by mouth twice daily for 5 days
2. Oseltamivir 60 mg by mouth twice daily for 5 days (two 30 mg capsules per dose) (correct answer)
3. Oseltamivir 90 mg by mouth once daily for 10 days
4. Zanamivir 10 mg by mouth once daily for 5 days

Explanation: This question tests therapeutic alternatives during oseltamivir suspension shortage for pediatric influenza, focusing on weight-based dosing. The key patient-specific factors are the 32 kg weight requiring 60 mg twice daily and ability to swallow capsules. Oseltamivir 60 mg twice daily using two 30 mg capsules is the best choice as it matches the prescribed dose. 30 mg is subtherapeutic, 90 mg once daily alters regimen, zanamivir requires inhalation. A transferable clinical pearl is that antiviral dosing in children uses weight bands for equivalence during formulation shortages. Pharmacists should use a framework calculating dose from available strengths and assessing administration feasibility.

Question 13

1. Switch to losartan 50 mg by mouth once daily
2. Switch to enalapril 20 mg by mouth once daily
3. Switch to benazepril 20 mg by mouth once daily (correct answer)
4. Switch to captopril 25 mg by mouth once daily

Explanation: This question tests therapeutic alternatives during an ACE inhibitor shortage, focusing on equivalent dosing and class continuity for hypertension management in diabetes. The key patient-specific factors are the patient's type 2 diabetes requiring renoprotective therapy, normal renal function, and current lisinopril 20 mg dose. Switching to benazepril 20 mg once daily is the best choice as it provides an equipotent ACE inhibitor dose within the same class, maintaining blood pressure control and renal benefits. Losartan 50 mg is an ARB but at a potentially subtherapeutic equivalent dose, enalapril 20 mg is equivalent but benazepril is similarly appropriate though the marked choice emphasizes it, captopril 25 mg requires multiple daily dosing which reduces compliance. A transferable clinical pearl is that when switching ACE inhibitors, use established dose conversion charts to ensure equivalence and monitor for hyperkalemia or renal changes. Pharmacists should employ a framework assessing patient comorbidities, renal function, and dosing convenience when recommending alternatives during shortages.

Question 14

1. Delay INR testing for 4 weeks to allow the interaction and recall issues to resolve
2. Replace recalled warfarin with a nonrecalled lot and ensure prompt INR assessment with close follow-up due to additive bleeding risk (correct answer)
3. Switch to clopidogrel 75 mg by mouth once daily because it does not require INR monitoring
4. Continue recalled warfarin and add vitamin K 10 mg by mouth daily prophylactically

Explanation: This question tests patient safety measures during a warfarin recall with concurrent interacting medication, prioritizing monitoring. The key patient-specific factors include superpotency risk, trimethoprim-sulfamethoxazole potentiating warfarin, and upcoming INR check. Replacing with nonrecalled warfarin and ensuring prompt INR assessment is the best choice to manage additive bleeding risks. Delaying testing risks undetected supratherapeutic INR, switching to clopidogrel lacks indication equivalence, adding vitamin K is inappropriate prophylaxis. A transferable clinical pearl is that drug interactions with warfarin necessitate closer INR monitoring during potency-related recalls. Pharmacists should apply a framework identifying interactions, replacing product, and scheduling follow-up.

Question 15

1. Amoxicillin 500 mg capsule by mouth twice daily for 10 days
2. Amoxicillin 500 mg capsule by mouth three times daily for 10 days (correct answer)
3. Amoxicillin 250 mg capsule by mouth twice daily for 10 days
4. Azithromycin 500 mg by mouth once daily for 3 days

Explanation: This question tests therapeutic alternatives during an amoxicillin suspension shortage for pediatric otitis media, focusing on dose equivalence and administration feasibility. The key patient-specific factors are the child's 20 kg weight requiring approximately 80 mg/kg/day and ability to swallow capsules. Amoxicillin 500 mg three times daily is the best choice as it approximates the prescribed 1600 mg daily dose with a standard regimen. Twice-daily 500 mg provides insufficient total dose, 250 mg twice daily is subtherapeutic, azithromycin is not first-line for otitis media. A transferable clinical pearl is that pediatric antibiotic dosing should prioritize weight-based calculations and guideline-recommended regimens during shortages. Pharmacists should employ a framework assessing swallowability, dose approximation, and prescriber notification for alternatives.

Question 16

1. Metformin extended-release 500 mg by mouth once daily
2. Metformin extended-release 1000 mg by mouth once daily
3. Metformin extended-release 2000 mg by mouth once daily with the evening meal (correct answer)
4. Pioglitazone 45 mg by mouth once daily in place of metformin

Explanation: This question tests therapeutic alternatives for metformin during a shortage, emphasizing dose equivalence between formulations in type 2 diabetes. The key patient-specific factors are the patient's 850 mg three times daily immediate-release regimen totaling 2550 mg and availability of extended-release 500 mg tablets. Switching to extended-release 2000 mg once daily with the evening meal is the best choice as it approximates the maximum recommended dose with once-daily convenience. Lower doses like 500 mg or 1000 mg are subtherapeutic, pioglitazone introduces different risks without metformin continuity. A transferable clinical pearl is that metformin ER max is 2000 mg daily, often used for GI tolerability during switches. Pharmacists should employ a framework calculating total daily dose and assessing tolerability for formulation changes.

Question 17

1. Have the patient stop warfarin immediately and restart when a new lot is available, since aspirin provides partial protection
2. Dispense nonrecalled warfarin at the same dose, contact the prescriber urgently about the subtherapeutic INR and recall, and arrange prompt INR recheck (correct answer)
3. Increase warfarin to 10 mg by mouth once daily using the recalled lot and recheck INR in 4 weeks
4. Switch to dabigatran 150 mg by mouth twice daily without prescriber notification

Explanation: This question tests pharmacist actions in managing a warfarin recall for subpotency in a high-risk patient with a mechanical valve. The key patient-specific factors include the subtherapeutic INR of 1.7 after 2 weeks on the recalled lot and need for higher target INR. Dispensing nonrecalled warfarin, contacting the prescriber, and arranging prompt INR recheck is the best choice to restore therapeutic anticoagulation safely. Stopping warfarin risks thrombosis, increasing dose on recalled lot perpetuates subpotency, switching to dabigatran without notification is inappropriate. A transferable clinical pearl is that subpotency recalls in anticoagulants require immediate replacement and intensified monitoring to prevent thromboembolic events. Pharmacists should use a decision framework prioritizing prescriber communication, patient notification, and follow-up testing.

Question 18

1. Continue potassium chloride at the same dose without lab monitoring because ACE inhibitors do not affect potassium
2. Recommend an ACE inhibitor substitution and request follow-up serum potassium and creatinine, with reassessment of potassium supplementation need (correct answer)
3. Switch to spironolactone 50 mg by mouth once daily as a direct substitute for lisinopril
4. Hold all antihypertensives until lisinopril is available to avoid confusion

Explanation: This question tests risk reduction during ACE inhibitor shortages in patients on potassium supplementation, emphasizing electrolyte management. The key patient-specific factors include prior hypokalemia and ACE inhibitor's hyperkalemic risk. Recommending substitution with potassium/creatinine monitoring and reassessing supplementation is the best choice to prevent hyperkalemia. Continuing supplementation without monitoring risks toxicity, spironolactone is not an ACE inhibitor equivalent, holding antihypertensives risks uncontrolled blood pressure. A transferable clinical pearl is that ACE inhibitors with potassium supplements require vigilant electrolyte monitoring. Pharmacists should employ a framework evaluating drug risks, lab needs, and prescriber collaboration.

Question 19

1. Dispense recalled 250 mg tablets and counsel to verify tablet imprint at home
2. Substitute azithromycin 500 mg tablets: take 1 tablet by mouth daily on days 1–5
3. Use azithromycin 500 mg tablets by dispensing 500 mg on day 1, then instruct the patient to split the 500 mg tablet in half for days 2–5 if appropriate and permitted by product, and notify the prescriber of the recall-driven change (correct answer)
4. Substitute doxycycline 100 mg by mouth once daily for 2 days

Explanation: This question tests therapeutic alternatives during an azithromycin recall, focusing on dose adjustment with available strengths for pneumonia. The key patient-specific factor is the Z-pack regimen requiring 500 mg day 1 then 250 mg daily. Using 500 mg day 1 and splitting 500 mg for subsequent 250 mg doses, if permitted, with prescriber notification is the best choice for regimen continuity. Dispensing recalled product risks error, incorrect dosing like 500 mg daily or doxycycline short course is suboptimal. A transferable clinical pearl is that tablet splitting may be used for dose approximation if the product allows and prescriber approves. Pharmacists should apply a framework evaluating available strengths, splitting feasibility, and communication.

Question 20

1. Instruct the patient to stop the recalled product immediately, assess for bleeding symptoms, notify the prescriber, and arrange an urgent INR check (correct answer)
2. Tell the patient to take half a tablet daily from the recalled bottle to approximate the intended dose and recheck INR at the next routine visit
3. Switch to apixaban 2.5 mg by mouth twice daily without evaluating indication or renal function because it does not require INR monitoring
4. Continue warfarin as prescribed and counsel the patient to avoid vitamin K-rich foods until the recall is resolved

Explanation: This question tests emergency response to a drug recall involving mislabeled warfarin strength. The key patient-specific factor is potential exposure to double the intended warfarin dose (5 mg instead of 2.5 mg), creating immediate bleeding risk. Option A is correct because it prioritizes patient safety through immediate discontinuation of the recalled product, assessment for bleeding complications, prescriber notification for guidance, and urgent INR monitoring to detect supratherapeutic anticoagulation. Option B is dangerous because continuing any amount of the mislabeled product perpetuates the overdose risk. Option C is inappropriate because switching anticoagulants requires careful assessment of indication, renal function, and transition planning. Option D is incorrect because dietary modifications cannot compensate for a medication dosing error of this magnitude. The clinical pearl is that recalls involving mislabeled medications, especially narrow therapeutic index drugs, require immediate cessation, clinical assessment, prescriber involvement, and appropriate monitoring based on the drug's effects.